Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb Tarceva study in advanced pancreatic cancer
2005-004605-29Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erlotinib in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Roche. Primary endpoints: Serious adverse events, Adverse events leading to premature withdrawal and 5 more. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2005-004605-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004605-29.